Vertex Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRTX Vertex Pharmaceuticals Inc
HBI HanesBrands Inc
TMKR Tastemaker Acquisition Corp
SPY SPDR® S&P 500 ETF Trust
STOR STORE Capital Corp
PIPP^ Pine Island Acquisition Corp
PEP PepsiCo Inc
$NASI5000LMN NASDAQ Asia Cnsmr Svcs Large Mid Cap
PNM PNM Resources Inc
CBLAQ CBL & Associates Properties Inc
Go

Health Care : Biotechnology | Large Cap Growth
Company profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Closing Price
$211.98
Day's Change
4.19 (2.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
212.60
Day's Low
206.39
Volume
(Light)
Volume:
1,704,848

10-day average volume:
2,342,889
1,704,848

Display:

Providers:

UpdateCancel
6 providers
February 24, 2021
Vertex to Present at the Cowen Health Care Conference on March 2

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET. The audio portion of management's remarks will be available live through...(BusinessWire)

February 03, 2021
An Aging Population is Increasing the Need for Novel Treatments

With the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population has tripled in size over the past 40 years. The elderly are at a higher risk of contracting diseases...(PR Newswire)

February 01, 2021
Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results

---Full-year 2020 non-GAAP product revenues of $6.20 billion, a 55% increase compared to full-year 2019- ---Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today...(BusinessWire)

Vertex Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 1, 2021 / Vertex Pharmaceuticals, Inc. (FRA:VX1) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 1, 2021 at 4:30 PM Eastern Time. (Accesswire)

January 28, 2021
Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)

--- VX-880 is the first stem cell-derived therapy evaluating fully differentiated pancreatic islet cells for the treatment of T1D - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA)...(BusinessWire)

January 26, 2021
Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) to expand the use of TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and...(BusinessWire)

January 22, 2021
Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access...(BusinessWire)

January 07, 2021
Vertex to Present at the J.P. Morgan Healthcare Conference on January 11

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET (6:10 a.m. PT). The audio portion of management's remarks can be...(BusinessWire)

December 28, 2020
Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its New Drug Submission for TRIKAFTA(R), Vertex's investigational triple combination medicine, has been accepted for Priority Review by Health Canada for the treatment of cystic...(BusinessWire)

December 22, 2020
Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases

--Skyhawk receives $40 million upfront as well as potential milestones and royalty payments on future sales Skyhawk Therapeutics, Inc. and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today a strategic research collaboration and...(BusinessWire)

December 21, 2020
Vertex Announces FDA Approvals of TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO(R) (tezacaftor/ivacaftor and ivacaftor) and KALYDECO(R) (ivacaftor) for Use in People With CF With Certain Rare Mutations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for TRIKAFTA(R) (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.